Business Description
Relay Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US75943R1023
Share Class Description:
RLAY: Ordinary SharesDescription
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.03 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.74 | |||||
| Beneish M-Score | 12.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.5 | |||||
| 3-Year EBITDA Growth Rate | -35.5 | |||||
| 3-Year EPS without NRI Growth Rate | 19.3 | |||||
| 3-Year FCF Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | -11.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.01 | |||||
| 9-Day RSI | 42.34 | |||||
| 14-Day RSI | 38.42 | |||||
| 6-1 Month Momentum % | 19.59 | |||||
| 12-1 Month Momentum % | -33.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 25.44 | |||||
| Quick Ratio | 25.44 | |||||
| Cash Ratio | 24.78 | |||||
| Days Sales Outstanding | 3.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.3 | |||||
| Shareholder Yield % | -1.78 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1485.25 | |||||
| Net Margin % | -1338.66 | |||||
| FCF Margin % | -1191.74 | |||||
| ROE % | -40.96 | |||||
| ROA % | -35.25 | |||||
| ROIC % | -386.48 | |||||
| ROC (Joel Greenblatt) % | -524.98 | |||||
| ROCE % | -41.57 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 28.9 | |||||
| PB Ratio | 1.08 | |||||
| Price-to-Tangible-Book | 1.08 | |||||
| EV-to-EBIT | -0.31 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Revenue | 4.62 | |||||
| EV-to-Forward-Revenue | 104.54 | |||||
| EV-to-FCF | -0.39 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | -322.58 | |||||
| FCF Yield % | -36.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLAY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relay Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 25.546 | ||
| EPS (TTM) ($) | -2.8 | ||
| Beta | 1.57 | ||
| Volatility % | 71.21 | ||
| 14-Day RSI | 38.42 | ||
| 14-Day ATR ($) | 0.446899 | ||
| 20-Day SMA ($) | 6.73775 | ||
| 12-1 Month Momentum % | -33.54 | ||
| 52-Week Range ($) | 5.7 - 13.32 | ||
| Shares Outstanding (Mil) | 132.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relay Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relay Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Relay Therapeutics Inc Frequently Asked Questions
What is Relay Therapeutics Inc(RLAY)'s stock price today?
The current price of RLAY is $6.37. The 52 week high of RLAY is $13.32 and 52 week low is $5.70.
When is next earnings date of Relay Therapeutics Inc(RLAY)?
The next earnings date of Relay Therapeutics Inc(RLAY) is 2024-05-03 Est..
Does Relay Therapeutics Inc(RLAY) pay dividends? If so, how much?
Relay Therapeutics Inc(RLAY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers